

May 23, 2022



## Ceapro Inc. to Present at the H.C. Wainwright Global Investment Conference

EDMONTON, Alberta, May 23, 2022 (GLOBE NEWSWIRE) -- [Ceapro Inc.](#) (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that [Gilles Gagnon, President and Chief Executive Officer](#), of Ceapro, will present at the [H.C. Wainwright Global Investment Conference](#) being held May 23-26, 2022 in Miami, FL and virtually.

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the [conference website](#).

A [video webcast](#) of the presentation will be accessible for viewing on-demand beginning on Tuesday, May 24, 2022 at 7:00 AM ET for those registered for the event and will be available on the [Events](#) page in the [Investors](#) section of the Company’s website ([ceapro.com](#)). A webcast replay will be archived for 90 days following the event.

### About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company’s website at [www.ceapro.com](#).

### For more information contact:

Jenene Thomas  
JTC Team, LLC  
Investor Relations and Corporate Communications Advisor  
T (US): +1 (833) 475-8247  
E: [czo@jtcir.com](mailto:czo@jtcir.com)



Source: Ceapro Inc.